Biophytis Forms SAB for Phase 2 Obesity Study

Biophytis SA, a clinical-stage biotechnology firm, has announced the establishment of a Scientific Advisory Board (SAB) to support its phase 2 OBA clinical study focused on obesity. The new board will consist of globally recognized medical experts, including Professor Dennis Villareal from the United States and Professor Francisco Guarner from Spain. They will provide guidance on the development of Biophytis' drug BIO101, which is intended to be used in conjunction with GLP1-RA for treating obesity.

Professor Villareal, a specialist in endocrinology, diabetes, and metabolism at Baylor College of Medicine in Houston, Texas, highlighted the need for a clinical study to determine if a drug like BIO101 can maintain muscle strength during weight-loss therapy for obese patients. He noted that while GLP-1 agonists have been successful in aiding weight loss, they may also result in muscle mass reduction.

Biophytis' CEO, Stanislas Veillet, expressed his enthusiasm for the appointment of Professors Villareal and Guarner to the SAB. He emphasized Villareal's expertise in managing obese patients and his role in a previous phase 2 study on sarcopenia. Professor Guarner, known for his research on liver cell protection with prostaglandins, is a professor of internal medicine, gastroenterology, and hepatology at the Hospital Clinic in Barcelona and the University Clinic of Navarra.

Biophytis is preparing to submit an Investigational New Drug (IND) application to the FDA to initiate the OBA phase 2 clinical study in the United States. The company is based in Paris, France, and Cambridge, Massachusetts, and is focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is a small molecule being developed for muscular, respiratory, and metabolic diseases.

Biophytis SA is a clinical-stage biotechnology company that specializes in developing therapeutics for diseases associated with aging. Their lead drug candidate, BIO101, is in various stages of development for treating sarcopenia, Duchenne muscular dystrophy, Covid-19, and obesity. The company's shares are listed on both Euronext Growth and the Nasdaq Capital Market.